Quince Therapeutics (QNCX) Preferred Stock Liabilities (2018 - 2019)
Quince Therapeutics (QNCX) posted Preferred Stock Liabilities of $87.0 million for Q1 2019, little changed on a QoQ basis from $86.9 million in Q4 2018, and up 406.23% year-over-year from $17.2 million in Q1 2018.
Powered by 
Analysis
Quince Therapeutics (QNCX) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Quince Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $87.0 million in Q1 2019.
- On a quarterly basis, Preferred Stock Liabilities rose 406.23% year-over-year to $87.0 million in Q1 2019; TTM through Mar 2019 was $87.0 million, a 406.23% increase from a year earlier, with the FY2018 full-year figure at $86.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $87.0 million for Q1 2019 at Quince Therapeutics, roughly flat from $86.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $87.0 million in Q1 2019, with the low at $17.2 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Quince Therapeutics | 175.52 Mn | 175.52 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2019 | 86.96 Mn |
| Dec 31, 2018 | 86.87 Mn |
| Sep 30, 2018 | 86.78 Mn |
| Jun 30, 2018 | 86.72 Mn |
| Mar 31, 2018 | 17.18 Mn |